Levocetirizine dihydrochloride/Montelukast Sodium

盐酸左西替利嗪/孟鲁司特钠

Report date: 2026/02/03 16:32:42

Base Information

Drug NameLevocetirizine dihydrochloride/Montelukast Sodium
Drug Alias Name孟鲁司特钠/盐酸左西替利嗪Levocetirizine dihydrochloride and Montelukast SodiumMontelukast Sodium and Levocetirizine dihydrochlorideLevocetirizine/MontelukastMontelukast/levocetirizine +[7] 
ClassificationSmall molecules
Mechanisms of ActionCysteinyl leukotriene receptor 1 antagonistsHistamine H1 receptor antagonists
TargetsCysteinyl leukotriene receptor 1Histamine H1 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Rhinitis, Allergic, PerennialRhinitis, Allergic +[5] 
Global Approved IndicationsRhinitis, AllergicAsthma
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2017/05/16
Country/TerritoryUnited StatesSouth Korea
CombinationsYes MontelukastLevocetirizine dihydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Rhinitis, AllergicAsthma
Inactive IndicationsRhinitis, Allergic, PerennialRhinitis

Other Information

ATC CodeN/A
Related LinksN/A